Citation	Primary Reason for Exclusion
Tanner JA, Davies PE, Voudouris NC, Shahmirian A, Herbert D, Braganza N, Guglia A, Dechairo BM, Kennedy JL. Combinatorial pharmacogenomics and improved patient outcomes in depression: treatment by primary care physicians or psychiatrists. J Psychiatr Res. 2018;104:157-62.	Comparator (not comparative)
Olson MC, Maciel A, Gariepy JF, Cullors A, Saldivar JS, Taylor D, Centeno J, Garces JA, Vaishnavi S. Clinical impact of pharmacogenetic-guided treatment for patients exhibiting neuropsychiatric disorders: a randomized controlled trial. Prim Care Companion CNS Disord. 2017;19(2).	Population (not limited to depression)
Espadaler J, Tuson M, Lopez-Ibor JM, Lopez-Ibor F, Lopez-Ibor MI. Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis. CNS Spectr. 2016;22:315-24.	Population (not limited to depression)
Winner JG, Carhart JM, Altar CA, Goldfarb S, Allen JD, Lavezzari G, Parsons KK, Marshak AG, Garavaglia S, Dechairo BM. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res & Opin. 2015;31(9):1633-43.	Population (not limited to depression)
Breitenstein B, Scheuer S, Pfister H, Uhr M, Lucae S, Holsboer F, Ising M, Bruckl TM. The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study. CNS Spectrums. 2014;19:165-75.	Intervention (not a multi-gene decision-support tool)
Fagerness J, Fonseca E, Hess GP, et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care. 2014;20(5):e146-e156.	Population (not limited to depression)
Rundell JR, Harmandayan M, Staab JP. Pharmacogenomic testing and outcome among depressed patients in a tertiary care outpatient psychiatric consultation practice. Transl Psychiatry. 2011;1:e6.	Intervention (not limited to multi-gene decision-support tools)